<DOC>
	<DOCNO>NCT00045630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell decrease need surgery . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow observation surgery remove bladder ( cystectomy ) treat patient stage II stage III cancer urothelium .</brief_summary>
	<brief_title>S0219 , Combination Chemotherapy Followed By Observation Surgery Patients With Stage II Stage III Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - Determine pathologic complete response patient stage II III transitional cell cancer urothelium treat neoadjuvant gemcitabine , paclitaxel , carboplatin follow observation immediate cystectomy . - Determine , preliminarily , molecular marker predict response , survival , tumor recurrence patient treat regimen . - Determine recurrence rate cystectomy-free survival patient choose observation initial response neoadjuvant chemotherapy . - Compare survival patient treat neoadjuvant chemotherapy follow cystectomy vs observation . - Determine feasibility , tolerability , toxicity regimens patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute paclitaxel IV 30 minute day 1 8 carboplatin IV 30 minute day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Within 4-8 week completion neoadjuvant chemotherapy , patient undergo third transurethral resection bladder tumor . Patients T0 disease neoadjuvant chemotherapy may choose undergo observation . These patient undergo cystoscopies biopsy every 3 month 1 year , every 4 month 1 year , every 6 month disease progression . Patients T1 disease great neoadjuvant chemotherapy undergo immediate cystectomy . Patients T0 disease may also choose option . Patients undergo immediate cystectomy follow every 6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 95 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm muscleinvasive ( T2T4a ) , nodenegative ( N0 ) urothelial transitional cell cancer ( TCC ) bladder Focal squamous and/or adenocarcinoma differentiation , define â‰¤ 10 % tumor volume allow The following diagnosis allow : Small cell carcinoma Sarcomatoid component Disease diagnose initial transurethral resection bladder tumor ( TURBT ) second TURBT perform within 8 week first attempt remove tumor present Residual disease second TURBT allow No 1456 day second TURBT No metastatic disease chest xray CT scan MRI abdomen pelvis Fresh tumor tissue , paraffin tumor tissue , unstained slide , cell block specimen one TURBTs available PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic White blood cell count ( WBC ) least 3,500/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least low limit normal Hepatic Bilirubin great 1.5 mg/dL Aspartate aminotransferase ( SGOT ) great 2 time upper limit normal Renal Creatinine great 2.0 mg/dL AND/OR Creatinine clearance least 60 mL/min Other No prohibitive medical risk would preclude radical cystectomy No serious concurrent systemic disorder would preclude study compliance No malignancy except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission , cancer patient diseasefree 5 year Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Prior intravesical immunotherapy allow Chemotherapy No prior systemic chemotherapy TCC urothelium Prior intravesical chemotherapy allow Endocrine therapy Not specify Radiotherapy No prior radiotherapy TCC urothelium No concurrent radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>anterior urethral cancer</keyword>
	<keyword>localize transitional cell cancer renal pelvis ureter</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>